Answers are grounded in this paper and cite their sources.
The challenges to understanding the biology of cancer lies in its heterogeneity that makes each type of cancer a cluster of different subtypes. This diversity not only increases the complexity of the disease but also makes every cancer unique in its composition. Over the past decades, researchers have amassed a tremendous understanding of a vast array of cancers driven by different mutations, responses of the immune system to tumors, symbiotic relationship of cancer cells with the tumor microenvironment, as well as reprogramming of various anabolic and catabolic processes. The emergence of genetic technologies and structural biology approaches have allowed researchers to rapidly sequence and study cancer genomes and epigenomes, revealing genetic alterations. Tremendous technological advances have enabled studying the whole proteome and/or metabolome that helps us to understand interactions with other proteins and effects on cellular behavior. Additionally, combination therapies targeting cancer stem cells have allowed for better treatment modalities for both chemoresistant solid tumors and hematologic cancers over the course of their progression. Development of organoid cultures from patient tumors have helped analyze different yet concerted signaling cues in individual cells revealing how tumors respond to drugs. This has allowed for the development of more effective drugs and selection of the best course of treatment for individual patients; dawning in a new era of personalized precision medicine. Some of these validated discoveries go on to identify clinically useful biological indicators or biomarkers or are developed into potential diagnostic techniques. Diagnostic, prognostic, or predictive biomarkers allows us to address the inherent complexity and the ever-shifting genetic landscape of cancer. There has been a significant advancement in the field that allows prediction, detection, location, as well as therapy monitoring of patients with cancer. Newer technologies are, however, required to address the challenges faced by existing diagnostic techniques to improve the sensitivity and specificity of detection as well as recurrence at an early stage. This research topic is dedicated to articles (a) illustrating the identification of potential diagnostic indicators in cancer detection and prognosis, (b) highlighting novel technologies to further our understanding about cancer metabolism, and (c) evaluating applications of existing techniques and treatment modalities for cancer therapy. Emerging evidences demonstrate the utility of noncoding RNAs (ncRNA) as a biological marker in different cancers. Aberrant expression of the small nucleolar RNA (snoRNAs), a family of ncRNAs, and their association with the diagnosis as well as prognosis have been reported in distinct cancer types. Additionally, snoRNAs are reportedly stable and lie within detectable ranges in extracellular fluids, such as blood plasma, serum or urine; making it a potential candidate to become a cancer biomarker. In this research topic, Liu et al report the role of snoRNA host gene 18 as a tumor suppressor in hepatocellular carcinoma (HCC) and its correlation with tumor grade. Furthermore, plasma snoRNA host gene 18 displayed a greater specificity and sensitivity in HCC patients with relatively lower levels of alpha fetoprotein levels when compared to patients with hepatitis B and cirrhosis. The robustness of both circulating and tissue specific snoRNA host gene 18 expression makes it a potential diagnostic indicator to distinguish HCC from cirrhosis and aid in early detection. Detection and diagnosis by in situ tissue biopsies are challenged by (a) inaccessible anatomical location of the tissue, (b) safety risk and excruciating discomfort to the patients, (c)
No takes yet. Share an insight, caveat, or question.
Biswas et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: